Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of carboplatin, topotecan, and vinorelbine is a chemotherapy regimen that has been studied in clinical trials for various types of cancer. This combination brings together three different anticancer agents, each with its own mechanism of action and toxicity profile. Carboplatin is a platinum-based chemotherapy agent that works by forming DNA crosslinks, thereby inhibiting DNA synthesis and function. Topotecan is a topoisomerase I inhibitor derived from camptothecin that prevents DNA unwinding during replication. Vinorelbine is a vinca alkaloid that disrupts microtubule assembly, preventing cell division.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Carboplatin, Topotecan, and Vinorelbine Combination Therapy.